Filing Flows › Comparisons › NSPR vs AURX
InspireMD vs Nuo Therapeutics: NSPR and AURX compared
InspireMD is the larger company: $1.8M of revenue in its latest quarter (Q2 2026) against $1.8M for Nuo Therapeutics (Q2 2026). Nuo Therapeutics is growing faster (+153% against -0.4% a year earlier). Nuo Therapeutics is more profitable, with an operating margin of -9.4% against -815.6%.
Where the money goes: NSPR and AURX
InspireMD (NSPR) · Q2 2026
InspireMD, Q2 2026: revenue $1.8M (-0.4% year over year), operating margin -815.6%, net loss $14.3M, operating cash flow −$10.9M. The chart follows the revenue to costs, profit and cash.
Nuo Therapeutics (AURX) · Q2 2026
Nuo Therapeutics, Q2 2026: revenue $1.8M (+153% year over year), operating margin -9.4%, net loss $278K, operating cash flow −$236K. The chart follows the revenue to costs, profit and cash.
| InspireMD (NSPR) | Nuo Therapeutics (AURX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $1.8M | $1.8M |
| Revenue growth, Y/Y | -0.4% | +153% |
| Operating margin | -815.6% | -9.4% |
| Net earnings | −$14.3M | −$278K |
| Net margin | -808.8% | -15.7% |
| Operating cash flow | −$10.9M | −$236K |
Where the revenue comes from
Nuo Therapeutics
- Product: $1.7M (96%)
- Aurix and Private Label Centrifuge Devices: $72K (4%)
Questions
Which is bigger, InspireMD or Nuo Therapeutics?
InspireMD is the larger company: $1.8M of revenue in its latest quarter (Q2 2026) against $1.8M for Nuo Therapeutics (Q2 2026).
Is InspireMD or Nuo Therapeutics growing faster?
Nuo Therapeutics is growing faster (+153% against -0.4% a year earlier).
Which is more profitable, InspireMD or Nuo Therapeutics?
Nuo Therapeutics is more profitable, with an operating margin of -9.4% against -815.6%.
More: InspireMD earnings · how InspireMD makes money · Nuo Therapeutics earnings · how Nuo Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.